INSM: Ascending Triangle detected on 3 Jul 2026

Insmed is forming an ascending triangle pattern with current price at $111.60, support at $103.63, and resistance at $109.93. The structure score of 13/15 indicates a well-defined pattern with higher lows, while the solid breakout score of 13/13 and volume score of 10.5/12 suggest reasonable setup quality. The 60.95% win probability indicates above-average historical success for this pattern type. Price has gained 13.36% over two weeks and 6.82% in the past week, climbing toward resistance within bullish sector conditions (regime score +0.77).

Insmed reported 2025 net product revenues of $606.4M (up 67% vs 2024), driven by ARIKAYCE at $433.8M and BRINSUPRI at $172.7M. The UK approved BRINSUPRI for non-cystic fibrosis bronchiectasis in February 2026. ARIKAYCE global revenue grew 6% in Q1 2026 versus Q1 2025, driven by strong international growth. The company expects 2026 ARIKAYCE revenue of $450M–$470M with key Phase 3 ENCORE readout in March/April 2026 and Phase 2 CEDAR readout in Q2 2026. Analysts have raised Insmed's fair value estimate to $214.32, reflecting confidence in the Brinsupri launch and expanded market opportunity. The recent price action reflects growing market confidence in commercial execution and pipeline expansion.

A successful breakout above $109.93 resistance would target $116.10 (conservative measured move), representing a 4.0% upside from current levels. Volume confirmation is critical—the current volume ratio of 0.54 (well below the 20-day average of 5.1M shares) means any breakout requires a significant uptick in participation to validate the breakout. The RSI at 59.41 is neutral, providing room to run without overbought extremes. The setup fails below support at $103.63, invalidating the pattern. Historical win probability of 60.95% suggests roughly two-in-three breakout attempts succeed, making this above-average but not certain.

The Phase 2b CEDAR trial missed expectations on April 7, 2026, coinciding with modest stock declines. Company insiders have collectively sold $164M more than they bought in the last 12 months, signaling potential skepticism from management on current valuations. While a Japan regulatory decision for brensocatib is anticipated in 2026, Insmed is evaluating the impact of evolving US policy on future international launch timing. The stock's beta of 0.41 is low, but volatility at 0.6083 remains moderate. With current volume running at 54% of average, any negative catalyst could trigger a rapid descent toward support without sufficient buying interest to cushion the move. Upcoming Q2 2026 catalyst timing and broader healthcare policy shifts represent execution risks.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.